a Dipartimento di Medicina Sperimentale, U.O. Laboratorio di Analisi, Istituto Giannina Gaslini, Genoa, Italy, b Dipartimento di Malattie Respiratorie ed Allergiche, U.O. Allergologia, Azienda Ospedaliera Umberto I, Torrette, Ancona, Italy, c Istituto di Neurologia e Medicina Molecolare, CNR, Rome and II Università di Napoli, Naples, Italy, d U.O. Immunoallergologia, Università degli Studi di Firenze, Policlinico Careggi, Florence, Italy, e U.O. Laboratorio di Analisi, Ospedale San Martino, Genoa, Italy, f U.O. Pneumologia e Malattie Allergiche, Università di Genova, Genoa, Italy, g Rete di Allergologia Regione Piemonte, Cuneo, Italy, h U.O. Allergologia e Immunologia Clinica, Università di Bari, Bari, Italy
Objectives: To evaluate the performances of an allergen microarray in multi-sensitized allergic patients with respiratory symptoms.
Design and methods: 321 patients and 92 controls were included in this study. Specific serum IgE were assayed using ImmunoCAP ISAC, a microarray containing 103 components derived from 47 allergens and results were compared with extract-based ImmunoCAP Allergens sIgE to 15 common airborne allergens.
Results: The reproducibility of ISAC was good. The Positive Percent Agreement (PPA) varied between 75% and 100% for sIgE levels above 1 kUA/l. For samples with sIgE levels below 0.1 kUA/l, the Negative Percent Agreement (NPA) ranged between 90% and 100%. Notably, 58% of respiratory allergy patients had IgE to foodspecific proteins and 52% resulted sensitized to cross-reactive pan-allergens.
Conclusion: ImmunoCAP ISAC detects allergen sensitization at component level and adds important information by defining both cross and co-sensitization to a large variety of allergen molecules.